Clinical Trial

An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2017-08-02; most recent amendment 2025-09-14.
Status change: Recruiting → Active, Not Recruiting 2025-09-14
Status change: Not Yet Recruiting → Recruiting 2019-11-18
Trial Details
NCT Number NCT03240809
Lead Sponsor Bausch Health Americas, Inc.
Conditions Psoriasis
Enrollment 2 participants
Start Date 2020-01-24
Primary Completion 2028-12 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2025-09-16